Ramirez, Julio http://orcid.org/0000-0001-7801-5374
Carrico, Ruth
Wilde, Ashley
Junkins, Alan
Furmanek, Stephen
Chandler, Thomas
Schulz, Paul
Hubler, Robin
Peyrani, Paula
Liu, Qing
Trivedi, Sonali
Uppal, Sonal
Kalina, Warren V.
Falsey, Ann R.
Walsh, Edward E.
Yacisin, Kari
Jodar, Luis
Gessner, Bradford D.
Begier, Elizabeth
Funding for this research was provided by:
Pfizer Inc
Norton Healthcare
Article History
Received: 18 January 2023
Accepted: 6 April 2023
First Online: 6 May 2023
Funding
: This work was supported by Pfizer Inc., including supporting the journal’s rapid service fee. This study was conducted as a collaboration between Norton Infectious Diseases Institute, Norton Healthcare, and Pfizer. Norton Infectious Diseases Institute, Norton Healthcare is the study sponsor.
: Study concept and design was carried out by Elizabeth Begier, Robin Hubler, Julio Ramirez, Ruth Carrico, Ashley Wilde, Paula Peyrani, Ann R. Falsey, Edward Walsh, Luis Jodar, and Bradford D. Gessner. Data acquisition was performed by Julio Ramirez, Ruth Carrico, Ashley Wilde, Alan Junkins, Stephen Furmanek, Thomas Chandler, and Warren V Kalina. Data interpretation and analysis was performed by all authors. Writing the first draft was performed by Julio Ramirez and Stephen Furmanek. Participation in drafting or revision involved all authors.
: Julio Ramirez, Ruth Carrico, Ashley Wilde, Alan Junkins, Stephen Furmanek, Thomas Chandler, and Paul Schulz are employees of Norton, which received fees from Pfizer in relation to this study. Robin Hubler, Paula Peyrani, Qing Liu, Sonali Trivedi, Sonal Uppal, Warren V Kalina, Kari Yacisin, Luis Jodar, Bradford D. Gessner, and Elizabeth Begier are employees of Pfizer and may hold Pfizer stock and/or stock options. Ann R. Falsey has research grants from Pfizer, Janssen, CyanVac, and BioFire Diagnostics, served on the Data and Safety Monitoring Board for Novavax, and consulted for Arrowhead Pharmaceuticals. Edward E. Walsh has research grants from Merck and Pfizer and non paid consulting for Moderna and Pfizer.
: This study was approved (#21-N0325) by WCG IRB. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. All specimen and data collection were performed after informed consent was obtained.
: Data access may be requested from Pfizer data request portal: ExternalRef removed